GI Dynamics swaps CEOs | Personnel Moves

August 28, 2014 By Brad Perriello Leave a Comment

GI Dynamics (ASX:GID) said it’s replacing Stuart Randle as CEO with Michael Dale, the former chief at ATS Medical until its 2010 acquisition by Medtronic (NYSE:MDT).

Randle will stay on as a member of the GI Dynamics board and act as a consultant during the transition, according to a press release.

“On behalf of the entire GI Dynamics organization, I want to thank Stu for his significant contributions to the company over the last decade,” chairman Jack Meyer said in prepared remarks. “Stu was instrumental in securing the CE Mark for EndoBarrier, gaining Food & Drug Administration approval for initiating the pivotal clinical study for EndoBarrier in the United States and successfully completing critical financings, including the company’s initial public offering on the Australian Securities Exchange. We appreciate Stu’s leadership through these important milestones and his continued support during this CEO transition period.”

Dale led ATS Medical as chairman, president & CEO from 2002 until Medtronic acquired it in 2010 for $370 million. He had the corner office at Helical Solutions and also worked at Endocardial Solutions, Cyberonics (NSDQ:CYBX), St. Jude Medical (NYSE:STJ) and Edwards Lifesciences (NYSE:EW).

“Mike is an exceptional leader with an impressive track record in the medical device sector,” Randle said in a statement. “Building GI Dynamics has been an incredible journey over the last 10 years, and we are fortunate to have a leader of Mike’s caliber to drive the future success of the company. I look forward to making this a seamless transition for him and the rest of our organization.”

“I am delighted and honored by the opportunity to lead GI Dynamics,” Dale added. “When every stakeholder stands to benefit in meaningful ways from the application of a better solution to a significant problem, you have the basis for a great business. With the focus on better treatment of Type 2 diabetes and obesity, I believe GI Dynamics offers this potential. The growing body of clinical evidence in support of EndoBarrier is compelling and provides a strong foundation upon which to build. I look forward to working with the management team and the Board to develop the strategies required to fulfill our business purpose.”

Wright Medical loses extremities prez Stookey
Wright Medical (NSDQ:WMGI) said Eric Stookey, president of its extremities business, stepped down effective August 20. COO Pascal Girin will assume Stookey’s duties while Wright searches for a permanent replacement, the company said.
Read more

KCI CFO Hureau to step down next month
Robert Hureau, the CFO for Kinetic Concepts Inc. and sister companies LifeCell and Systagenix, is stepping down effective Sept. 23 “to pursue another career opportunity,” according to a press release. Hureau is slated to be replaced on an interim basis by controller Brian Busenlehner.
Read more

StemBioSys taps ex-KCI chief Burzik
Speaking of KCI, StemBioSys said it named former KCI CEO Catherine Burzik chairwoman, replacing founder Dr. Steven Davis.
Read more

HeartFlow adds vets from Intuitive Surgical, Medtronic, others
HeartFlow said it added a quartet of medical device veterans to its executive roster, naming former Intuitive Surgical (NSDQ:ISRG) finance vice president Baird Radford as CFO; Brent Ness, ex-Medtronic Navigation (NYSE:MDT) sales & marketing president, as chief commercial officer; Abbott acquisition OptiMedica’s marketing & sales vice president Robert Eno as vice president of marketing; and Yoshiki Kawabat, late of Adachi Co., as president of HeartFlow Japan.
Read more

Mojo Vision developing ‘smart’ contact lens
Mojo Vision is working with the FDA to develop a smart contact lens to help people with low vision. The lens overlays real-time contrast and lighting enhancements with zoom functionality and recently won FDA breakthrough device designation. “Receiving the Breakthrough Device Designation is a significant step in our research and development process. We look forward to… […]
FDA to EPA: Leave us out of your ethylene oxide rule
This article has been updated with comments from the FDA. The FDA has asked the Environmental Protection Agency to leave the FDA out of its proposal for stricter regulation of ethylene oxide (EtO) emissions, and the EPA complied. In an interagency comment on the EPA’s proposed rule governing commercial EtO users — which includes medical… […]
Clippart debuts stepper-controlled flow valve
Clippard recently launched a new stepper-controlled proportional valve for precision flow control. The Eclipse valve uses the industry’s most robust and powerful miniature linear actuator, according to Cincinnati-based Clippard. The patent-pending Eclipse is designed for liquid and gas delivery, medical, analytical and industrial automation requiring ultra-fine resolution and repeatability. The design also allows for custom… […]
Supporting regulatory affairs departments to address clinical requirements under new MDR
By Dietmar Falke and Jaap Laufer, Emergo Group The May 25, 2020 MDR deadline is approaching rapidly, and by now many medical device manufacturers are aware that the MDR requires the proactive collection of post-marketing clinical follow-up (PMCF) data. Get the full story here at the Emergo Group’s blog. The opinions expressed in this blog… […]
5 tips to raise funding for your medical device
Securing funding can be a long and tedious process, and medical device businesses must work to position themselves as especially attractive to potential investors to maximize success and accelerate the fundraising process. Jon Speer, Greenlight Guru According to Alejandro Cremades, author of The Art of Startup Fundraising, it can take from six to nine months… […]
FDA recognizes latest ISO 14971 as medical device consensus standard
By Mark Leimbeck and Stewart Eisenhart, Emergo Group The US Food and Drug Administration has granted Recognized Consensus Standard status to the third edition of the ISO 14071 risk management standard for medical devices and IVD products. Get the full story here at the Emergo Group’s blog. The opinions expressed in this blog post are… […]
Synaptive Medical updates Modus V surgical microscope
Synaptive Medical announced that its U.S. and Canadian Modus V robotic digital microscope now includes updates such as additional 3D visualization and voice-activated control. The Modus V is a robotically controlled digital microscope used as part of Synaptive’s BrightMatter surgical suite designed for less invasive, patient-specific approaches in complex cranial procedures. The Modus V provides similar… […]
New machine can preserve donor livers for 1 week
Researchers in Switzerland have built a perfusion machine that can preserve human livers for transplantation for a week or more, potentially slashing the number of donor livers that must be discarded due to time-related deterioration. Existing perfusion technology can preserve a donor liver for up to 24 hours. The team of surgeons, biologists and engineers… […]
Smiths Medical launches Portex tracheostomy tubes and kits
Smiths Medical this week launched its Portex polyvinyl chloride tracheostomy tube and kit portfolio. The new polyvinyl chloride (PVC) tube portfolio has options for a variety of patients, according to the company. “Our goal was to create tracheostomy tubes and kits designed to help clinicians provide the best patient care. We’re excited to offer a variety… […]
FDA clears Cleveland Clinic 3D-printed airway stents
The FDA recently cleared 3D-printed, patient-specific stents developed by a doctor at the Cleveland Clinic. Cleveland Clinic physician Tom Gildea developed the stents to keep open the airways of patients with serious breathing disorders caused by inflammation, trauma, tumors and other masses. Airway stents come in a limited number of sizes and shapes and are… […]
Boston Scientific shares drop on Q4 sales news
Shares in Boston Scientific (NYSE:BSX) dropped 8% this morning on news of disappointing fourth-quarter sales. The company’s preliminary earnings report showed sales for the quarter ended Dec. 31, 2019 coming in at $2.9 billion, below the $2.91 billion that analysts were expecting. The unaudited sales figure represents organic growth of 7.3%, missing the company’s own guidance of… […]